Weilizhibo-B (09887): LBL-034 presented an oral report on updated clinical data for relapsed/refractory multiple myeloma at the 2026 ESMO Conference

Zhitong Finance App News, Weilizhibo-B (09887) issued an announcement. On October 24, 2026, the updated results of the first human clinical study of LBL-034 (GPRC5D/CD3 bispecific T-cell adapter, TCE) for the treatment of relapsed/refractory multiple myeloma (RRMM) were presented in the form of an oral report at the 2026 European Society of Medical Oncology Annual Meeting (2026 ESMO). LBL-034 achieved deep and long-lasting relief in severely treated, high-risk patients with relapsed/refractory multiple myeloma (RRMM), while showing excellent safety characteristics, that is, the incidence of cytokine release syndrome (CRS) is low and manageable. This data provides strong clinical verification of the efficacy and safety of the conditional T-cell redirection and initiation mechanism unique to the company's LeadsBody™ TCE platform, and also lays a solid foundation for expanding the company's TCE pipeline from hematologic malignancies to autoimmune diseases and solid tumors.